Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003299 · ClinicalTrials.gov registry record · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
A NA study of Aortic Stenosis and Aortic Stenosis, Severe, sponsored by Edwards Lifesciences.
- Recruiting
- Registry status
- NA
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT03003299 is a NA study of Aortic Stenosis and Aortic Stenosis, Severe that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 125 participants, below the 1,357-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT03003299, a NA study of Aortic Stenosis and Aortic Stenosis, Severe, is actively recruiting participants, sponsored by Edwards Lifesciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Conditions Studied
Interventions
- DEVICE Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Study Locations (20)
California
- University of California Los Angeles - Los Angeles
- Sutter Medical Center - Sacramento
- Kaiser Permanente San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Illinois
- Northwestern University Hospital - Chicago
- Rush University Medical Center - Chicago
- Northshore University HealthSystem - Evanston
- Prairie Education and Research Cooperative - Springfield
Florida
- JFK Medical Center/ Atlantic Clinical Research Collaborative - Atlantis
- University of Florida, Gainesville - Gainesville
Michigan
- Henry Ford Hospital - Detroit
- William Beaumont Hospital - Royal Oak
Minnesota
- University of Minnesota Medical Center - Minneapolis
- Mayo Clinic - Rochester
Arizona
- Banner University Medical Center - Phoenix
Colorado
- UC Health Northern Colorado/Medical Center of the Rockies - Loveland
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2017-01-05 |
| Est. Completion | 2038-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03003299
The ClinicalTrials.gov registry entry for NCT03003299 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,357-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (91% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which Edwards SAPIEN 3/SAPIEN 3 Ultra THV is the first listed.
NCT03003299 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT03003299 about?
NCT03003299 is a clinical study titled "PARTNER 3 Trial - Aortic Valve-in-Valve". This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
What is the current status of trial NCT03003299?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2017-01-05. Estimated completion is 2038-04.
What conditions does trial NCT03003299 study?
This clinical trial studies the following conditions: Aortic Stenosis, Aortic Stenosis, Severe.
What interventions are being tested in trial NCT03003299?
The interventions under investigation include: Edwards SAPIEN 3/SAPIEN 3 Ultra THV (DEVICE).
Who is sponsoring clinical trial NCT03003299?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03003299 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacement Fibrosis
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
-
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
RECRUITING · NA
-
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
RECRUITING · NA
-
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)
ACTIVE NOT RECRUITING · NA
-
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.